Floatz logo

PARITAPREVIR

Severe Renal Impairment

AbbVieSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Severe Renal Impairment cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
Anna Cruceta
Phase 4BBB
Midodrine
Anna Cruceta
Phase 4BB
DEXAMETHASONE
Augusta University
Phase 3BB
Envarsus Product
University of Alberta
Phase 4BB
Empagliflozin
University Hospital, Basel, Switzerland
Phase 4BB

View all 50 →

Same molecule, other indications

PARITAPREVIR is also rated in:

hepatitis C virus infectionDormant
A
Indicative ·
87 / 100
View asset →
chronic hepatitis C virus infectionDormant
A
Indicative ·
82 / 100
View asset →
cirrhosis of liverDormant
A
Indicative ·
82 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →